| Primary information |
|---|
| ID | antitb_1607, |
| Name | 24411680 |
| N-Terminal modification | TP-5 |
| C-Terminal Modification | RKDVY |
| Chemical Modification | Free |
| Linear/Cyclic | Amidation |
| Length | None |
| Chirality | Linear |
| Nature | 4 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis RIF-susceptible |
| Cell Line | MIC = > 1000mg/L |
| Inhibition Concentration | in vitro |
| Sequence | 2014 |
| Cytotoxicity | RAW 264.7 mouse macrophage |
| In vivo Model | NA |
| Lethal Dose | HC50= > 2000 mg/L on Human RBC |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | Stimulate TNF-α production |
| Combination Therapy | Disrupt the mycobacterial membrane |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1611, |
| Name | 24411680 |
| N-Terminal modification | TP-5 |
| C-Terminal Modification | RKDVY |
| Chemical Modification | Free |
| Linear/Cyclic | Amidation |
| Length | None |
| Chirality | Linear |
| Nature | 4 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis RIF-Resistance |
| Inhibition Concentration | in vitro |
| Sequence | 2014 |
| Cytotoxicity | RAW 264.7 mouse macrophage |
| In vivo Model | NA |
| Lethal Dose | HC50= > 2000 mg/L on Human RBC |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | Stimulate TNF-α production |
| Combination Therapy | Disrupt the mycobacterial membrane |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |